Synthesis and use of dual tyrosyl-DNA phosphodiesterase I (Tdp1)—topoisomerase I (Top1) inhibitors
The invention described herein pertains to the synthesis and use of certain N-substituted indenoisoquinoline compounds which inhibit the activity Tyrosyl-DNA Phosphodiesterase I (Tdp1) or Topoisomerase I (Top1) or both, or otherwise demonstrate anticancer activity. Also disclosed are novel N-substituted indenoisoquinoline compounds and pharmaceutical compositions comprising the novel N-substituted indenoisoquinoline compounds.
1. A compound of the formula
or a pharmaceutically acceptable salt thereof,
wherein:
R T is amino, R a is 3-carboxymethylamino and R d is hydrogen; or
R T is amino, R a is 3-amino and R d is 9-methoxy; or
R T is amino, R a is 3-iodo and R d is hydrogen; or
R T is dimethylamino, R a is 3-iodo and R d is 9-methoxy; or
R T is dimethylamino, R a is 3-cyano and R d is hydrogen.
2. A pharmaceutical composition comprising a compound of claim 1 and one or more carriers, diluents, or excipients, or a combination thereof.
3. A compound of the formula
or a pharmaceutically acceptable salt thereof,
wherein:
n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 11, or 12,
R a represents 1-4 substituents each of which is independently selected from the group consisting of hydrogen, halo, hydroxy, optionally substituted (1-4C)alkyl, optionally substituted (1-4C)alkoxy, cyano, nitro, optionally substituted alkylthio, optionally substituted alkylsulfonyl, carboxylic acid and derivatives thereof, and sulfonic acid and derivatives thereof;
or R a represents 2-4 substituents where 2 of said substituents are adjacent substituents and are taken together with the attached carbons to form an optionally substituted heterocycle, and where any remaining substituents are each independently selected from the group consisting of hydrogen, halo, hydroxy, optionally substituted (1-4C)alkyl, optionally substituted (1-4C)alkoxy, cyano, nitro, optionally substituted (1-4C)alkylthio, optionally substituted (1-4C)alkylsulfonyl, carboxylic acid and derivatives thereof, and sulfonic acid and derivatives thereof; and
R d represents 1-4 substituents each of which is independently selected from the group consisting of hydrogen, halo, hydroxy, optionally substituted (1-4C)alkyl, optionally substituted (1-4C)alkoxy, cyano, nitro, optionally substituted (1-4C)alkylthio, optionally substituted (1-4C)alkylsulfonyl, phenyl (which may bear one or more amino, hydroxyl, halo, thiol, (1-6C)alkyl or halo(1-6C)alkyl substituents), carboxylic acid and derivatives thereof, and sulfonic acid and derivatives thereof; or R d represents 2-4 substituents where 2 of said substituents are adjacent substituents and are taken together with the attached carbons to form an optionally substituted heterocycle, and where any remaining substituents are each independently selected from the group consisting of hydrogen, halo, hydroxy, optionally substituted (1-4C)alkyl, optionally substituted (1-4C)alkoxy, cyano, nitro, optionally substituted (1-4C)alkylthio, optionally substituted (1-4C)alkylsulfonyl, carboxylic acid and derivatives thereof, and sulfonic acid and derivatives thereof;
R S is (1-6C)alkyl, (3-7C)cycloalkyl or phenyl, which phenyl may bear one or more amino, hydroxyl, halo, thiol, (1-6C)alkyl or halo(1-6C)alkyl substituents.
4. A pharmaceutical composition comprising a compound of claim 3 and one or more carriers, diluents, or excipients, or a combination thereof.
5. A compound of the formula
or a pharmaceutically acceptable salt thereof,
wherein:
R T is dimethylamino, R a is 3-cyano and R d is 8,9-methylenedioxy; or
R T is 4-morpholinyl, R a is 3-cyano and R d is hydrogen; or
R T is imidazolyl, R a is 3-cyano and R d is hydrogen.
6. A pharmaceutical composition comprising a compound of claim 5 and one or more carriers, diluents, or excipients, or a combination thereof.